LianBio Launches to Bring US Assets to China; Announces $719 Million of In-Licensings
Perceptive Advisors is launching LianBio to bring US biopharma assets to China. A successful fund operator, Perceptive has made investments in 150 public and 80 private biopharmas and has strong connections to them. With a paradigm-shifting assets and top drug developers in China, LianBio plans to build a strong China portfolio. Dr. Debra Yu, MD, President and Chief business Officer of LianBio, told ChinaBio Today in an exclusive interview, "Our unique feature is - we are moving beyond mere innovation to focus